Bernstein SocGen Group Reiterates Market Perform Rating on Pfizer (PFE), 'a sore loss for Pfizer' if Novo are successful in bid for Metsera

Go back to Bernstein SocGen Group Reiterates Market Perform Rating on Pfizer (PFE), 'a sore loss for Pfizer' if Novo are successful in bid for Metsera

Pfizer earnings preview: Leerink trims estimates

November 3, 2025 4:00 PM EST

Pfizer (NYSE: PFE) is set to report third-quarter results on Nov. 4, with analysts at Leerink Partners lowering earnings forecasts ahead of the release.

Leerink reduced its third-quarter earnings-per-share estimate by $0.10, or 13%, to $0.70, and full-year 2025 EPS by 3% to $3.04, within company guidance ($2.90$3.10).

The firm said it cut its 2025 Paxlovid... More